- Research article
- Open Access
Transcriptomic responses to prion disease in rats
© Herbst et al. 2015
Received: 8 April 2015
Accepted: 27 August 2015
Published: 5 September 2015
Prions diseases are fatal neurodegenerative diseases of mammals. While the molecular responses to prion infection have been extensively characterized in the laboratory mouse, little is known in other rodents. To explore these responses and make comparisons, we generated a prion disease in the laboratory rat by successive passage beginning with mouse RML prions.
We describe the accumulation of rat prions, associated pathology and the transcriptional impact throughout the disease course. Comparative transcriptional profiling between laboratory mice and rats suggests that similar molecular and cellular processes are unfolding in response to prion infection. At the level of individual transcripts, however, variability exists between mice and rats and many genes deregulated by prion infection in mice are not affected in rats.
Our findings detail the molecular responses to prion disease in the rat and highlight the usefulness of comparative approaches to understanding neurodegeneration and prion diseases in particular.
Prion diseases are an unusual class of fatal, transmissible, neurodegenerative disorders that affect the mammalian central nervous system. They are caused by the accumulation of an abnormal conformation of the normal host encoded cellular prion protein, PrPC. Although the exact mechanism is unknown, this conformational rearrangement of PrPC is thought to be brought about by template-directed misfolding wherein seed molecules of the abnormal isoform, PrPSc, convert PrPC into new PrPSc molecules. Laboratory investigation of prion diseases typically relies upon rodents, which can be infected with natural isolates of scrapie  albeit with some difficulty as ovid scrapie isolates need time to adapt to rodents. This adaptation is characteristic of interspecies transmission of prion infections and reflects the molecular adaptation that must occur to allow interaction between exogenous foreign PrPSc and host PrPC molecules, selecting for conformations which exhibit efficient template-directed prion-specific folding. In some cases, no conformational solution is found, reflecting a molecular species barrier to disease transmission.
In recent years, advances in genomic technologies have allowed unprecedented examination of the transcriptional responses induced by prion infection. These studies [2–9] have the aim of identifying pathways underlying the mechanism of prion-induced neurotoxicity. A second important aim has been to identify signature molecules that might act as surrogate biomarkers for these diseases as there are significant analytical challenges associated with sensitively detecting and specifically distinguishing PrPSc from normal PrPC. This work has most commonly been performed using laboratory mice as cross-sectional time course experiments can be performed, including the important pre-clinical asymptomatic phase of disease. Critically, however, the relevance and generalizability of mouse prion responses to prion diseases of other species is unknown. To begin addressing these issues, we adapted mouse RML prions into rats with the aim of identifying common prion disease transcriptional responses. Brain tissue from control and scrapie affected rats was transcriptionally profiled and genes whose expression was changed in response to prion diseases identified. We identified 712 genes differentially regulated in rat prion disease. Only 33 % of the rat genes with changes in expression were found to have similar responses in the corresponding mouse orthologs, questioning the universality of previous mouse gene expression profiles. This comparative approach allowed the identification of genes whose prion-induced expression change is conserved between mice and rats and highlights the significance of these genes. We show that Rat-Adapted Scrapie (RAS) is a powerful tool for an -omics based approach to decipher the molecular impact of prion disease in vivo, with applicability to the molecular mechanisms of disease and biomarker discovery.
Development of rat-adapted scrapie
Gene expression profiling of rat-adapted scrapie
Mice have been the preferred laboratory rodent for prion diseases research because they can be inexpensively housed and are amenable to transgenesis, facilitating short incubation periods upon over expression of PrP or examination of non-murine prion replication by exogenous PrP expression. Subsequent to the sequencing and annotation of the mouse genome and the development of high density transcriptional arrays for measurements of gene expression profiling, mice have been used extensively to examine the molecular pathology of prion disease probing the impact of prion and animal strain. To expand upon this foundation, we adapted mouse prions to rats. We reasoned that by taking a comparative approach to the molecular pathology of prion disease, inferences into the variability of the molecular response to prion diseases could be obtained. Finally, rats, like mice, can be used in a time course study of prion disease. This allows for the identification of early transcriptional responses to prion infection, responses which are particularly valuable for the identification of surrogate disease biomarkers.
To generate rat prion disease, we attempted to adapt six different prion disease agents to rats (Fig. 1). Of these six agents, only mouse RML prions were able to surmount the molecular species barrier to prion disease transmission. Mouse PrP differs from the rat by ten amino acid changes, seven in the mature protein and four in the N-terminal octa-peptide repeat region (Additional file 1: Figure S5.) As rat shares the most prion protein sequence identity with the mouse, is perhaps not surprising that the mouse-adapted agent transmitted whereas the other prion agents did not. The lack of transmission of the other agents may be explained based upon divergent amino acid residues that inhibit conversion of rat PrPC. For example, at position 113, mice and rats share a common leucine whereas the other prions tested contain methionine.
Our adaptation of mouse scrapie into rats appears similar to that process observed by Kimberlin and Walker . The increase in incubation period at second passage is due to our sacrificing first passage rats at 365 days post-inoculation despite a lack of clinical symptoms, whereas Kimberlin and Walker allowed the first passage animals to reach clinical disease. Slight increases in reported incubation periods in our experiments compared to the Kimberlin transmission, are due to different criteria for euthanizing animals; Kimberlin and Walker sacrificed rodents at the onset of clinical disease. The similarity of our rat-adapted scrapie with the Kimberlin rat transmission is supported by back passage and interspecies transmission experiments. Back passage of RAS to mice reestablished a strain that was indistinguishable from RML/Chandler with an incubation period of 158 days. Transmission of RAS into hamsters resulted in an incubation period of 154 days post infection after second passage. The passage of rat agent into mice and hamsters bears resemblance to that of Kimberlin and Walker and supports the conclusion that the two rat prion infections are similar. By third passage, the rat prions were fully adapted. Subsequent passages did not result in significant incubation period shortening and gene expression data from third passage clincially affected rats is substantially identical to fourth passage rats.
Rat-adapted scrapie exhibits features common to other prion diseases. A long preclinical phase precedes a rapid clinical period marked by a progressive neurological dysfunction with prominent ataxia, kyphosis and wasting. The protease resistant PrP observed is typical as is the widespread deposition of PrPSc in the brain. Spongiosis and reactive astrogliosis are as expected of a prion disease. Gene expression profiles from rats clinically affected with prion disease revealed a strong neuronal inflammation associated with proliferated and activated astrocytes. This is perhaps best observed through the up-regulation of GFAP, a hallmark of the molecular response to prion infection. GFAP was up-regulated 1.7, 2.6 and 3.5 fold at the 2 preclinical and clinical time points in rats.
Strategies comparing gene expression between mice and rats were undertaken to explore the level of conservation of prion disease transcriptomic responses. Analysis of both narrow and broad subsets of genes were undertaken to remove selection bias. Gene subsets were selected based upon stringent similarities in oligonucleotide probe design including identical gene regions in rat and mouse and high percent identity between orthologous probe pairs. In many cases, probes were identical. Broader examination of gene subsets were also undertaken to ascertain, more globally, the degree of similarity between the transcript profiles. Finally, mouse genes whose transcriptional responses were deregulated across different prion strain and mouse background combinations and considered central to prion disease were examined. Our comparative analyses of gene expression changes between mouse RML and rat-adapted scrapie suggest that there are differences in gene expression in response to prion disease at the level of individual transcripts, despite the fact that the overall response is neuro-inflammatory and many processes are conserved. Immune response processes are the most significant gene ontology categories identified in both mice and rats. This is consistent with the observed neuroinflammation that accompanies prion disease progression and pathogenesis.
One interpretation of the observed differences between mice and rats could be based upon strain phenomena. Prion strains result from conformational differences in the tertiary structures of PrPSc. Different strains of prions have different biochemical and biological properties, thus they might also elicit different molecular responses, observable in transcriptome type experiments. Gene Expression profiles of 301 V and RML on the same mouse background, however, show similar transcriptomic responses to prion disease . The variations observed in response to different prion strains are smaller than those observed between different strains of mice which are smaller than those observed in different species. Similarly recent comparisons of 22 L and RML mouse prion infections, which affect different brain regions, identified strikingly similar gene expression responses . Further, it is unlikely that evolution would have selected for distinct molecular neurodegenerative responses to different prion strains. At the whole brain level, species specific differences seem more important.
In this study, we describe the transmission and adaptation of mouse scrapie prions into rats. Comparative analysis of gene expression changes in mice and rat prion disease identified differences in gene expression of the level of individual genes, despite the fact that the overall profile is neuro-inflammatory and conserved. These data suggest caution in extrapolating solely from mouse prion gene expression data to prion infections in other species especially at the level of individual transcripts. Our data further show the utility of the laboratory rat as a useful prion disease research tool and demonstrate the power of comparative transcriptional profiling to explore the systems biology of prion diseases.
This study was carried out in accordance with the recommendations in the NIH Guide for Care and Use of Laboratory Animals and the guidelines of the Canadian Council on Animal Care. The protocols used were approved by the Institutional Animal Care and Use Committees at the University of Wisconsin and University of Alberta.
Rat transmission and adaptation
Prion agents used were the Rocky Mountain Lab (RML) strain of mouse-adapted scrapie, Stetsonville Transmissible Mink Encephalopathy  (TME), Hyper (Hy) strain of Hamster TME , 1st passage Skunk-adapted TME  prepared by transmission of TME into skunks and CWD from genetically defined deer transmissions . Six rats were infected with each prion at first and second passage.
Brains from animals clinically affected with prion disease were aseptically removed and prepared as 10 % (w/v) homogenates in sterile water. 10 % brain homogenate (50uL) was inoculated intracranially into weanling Wistar rats. After 1 year of incubation, preclinical rats from all infections were euthanized by CO2 inhalation and the brain excised, homogenized and analyzed by western blot. PrPSc positive samples (from the mouse RML transmission) were re-inoculated into naive animals. Subsequent serial passages were from rats clinically affected with rat-adapted scrapie.
Brains from rat passages were aseptically removed and bisected sagitally. Brain halves were reserved for immunohistochemistry (IHC) in formalin, or frozen on dry ice for immunoblotting, RNA isolation or subsequent passage. For IHC, tissues were fixed in 10 % buffered formalin, followed by antigen retrieval at 121C, 210 KPa in 10 mM citrate buffer for 2 min. After cooling to room temperature, sections were treated with 88 % formic acid for 30 min and 4 M guanidine thiocyanate for 2 h. Endogenous peroxidases were inactivated by 0.03 % hydrogen peroxide and tissue was blocked with 1 % normal mouse serum. Mouse anti-PrP mAB SAF83 (Cayman Chemical) was biotinylated and applied at a 1:250 dilution in blocking buffer overnight at 4C. Washes were performed in 10 mM PBS with 0.05 % Tween-20. Streptavidin-peroxidase (Invitrogen) was added for DAB color reaction. Anti-GFAP immunohistochemistry was performed as above but with the formic acid and guanidine treatment steps excluded. Mouse anti-GFAP mab G-A-5 (Sigma), was used at a 1:400 dilution.
Brain samples for immunoblot were treated with or without Proteinase K (Roche) at a ratio of 3.5ug PK/100ug protein at 50ug/mL for 30 min at 37C. Phosphotungstenic acid enrichments were performed as described [21, 22]. Bis-Tris SDS-PAGE was performed on 12 % polyacrylamide gels (Invitrogen) and transferred to PVDF. Immunoblotting was performed using mABs SAF83 (Cayman Chemical), 6H4 (Prionics), or 3 F10 (a kind gift from Yong-Sun Kim), all at a 1:20,000 dilution.
Gene expression profiling
RNA was extracted from frozen brain halves from infected and control animals with the QIAshredder and RNeasy mini kit (Qiagen, Valencia, CA) in accordance with the manufacturer’s recommendations. Due to the relatively large mass of rat brain, an initial homogenization was performed with a needle and syringe in 5 mL of buffer RLT, before further diluting an aliquot as per the manufacturer’s instructions. RNA was examined using a bioanalyzer(Agilent Technologies, Santa Clara, CA) to ensure the quality of isolated RNA. Total RNA was amplified and labeled in preparation for chemical fragmentation and hybridization with the MessageAmp Premier RNA amplification and labeling kit (Life Technologies, Grand Island, NY). Amplified and labeled cRNAs were hybridized on Affymetrix (Santa Clara, CA) rat genome 230 2.0 high density oligonucleotide arrays in accordance with the manufacturer’s recommendations. Three biological replicates were examined from infected and control rats at clinical disease following third passage and from each time point (113, 150 and 198 days post infection) of the fourth passage. Quantitative PCR validation assays were performed on cDNA samples by probe cleavage assays. RNA samples were normalized to the relative amounts of GAPDH and β-Actin. Three biological replicates and three technical replicates were analyzed for each gene and at each time point.
Differentially Expressed Genes were identified using Arraystar 5.0 (DNA Star, Madison, WI). Robust multiarray normalization using the quantile approach was used to normalize all microarray data. A moderated T-test with a multiple comparison adjustment  was used to reduce the false discovery rate, yet preserve a meaningful number of genes for pathway analysis. Pathway analysis was performed using the DAVID Bioinformatics database . Comparative analysis of genes induced by prions in mouse  and rat disease was performed on probe set matches generated by the Affymetrix comparison spreadsheets and matches obtained by using ENSEMBLE biomart release 78 [15, 24].
Availability of supporting data
The data sets supporting the results in this article are available in the NCBI GEO repository under accession GSE63930.
The authors would like to acknowledge Jing Yang for animal care, Nathalie Daude and Hristina Gapeshina for histology support. This work was funded by a grant from the Alberta Prion Research Institute and Alberta Innovates Bio Solutions.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Chandler RL. Encephalopathy in mice produced by inoculation with scrapie brain material. Lancet. 1961;1(7191):1378–9.View ArticlePubMedGoogle Scholar
- Booth S, Bowman C, Baumgartner R, Sorensen G, Robertson C, Coulthart M, et al. Identification of central nervous system genes involved in the host response to the scrapie agent during preclinical and clinical infection. J Gen Virol. 2004;85(Pt 11):3459–71. doi:10.1099/vir.0.80110-0.View ArticlePubMedGoogle Scholar
- Riemer C, Neidhold S, Burwinkel M, Schwarz A, Schultz J, Kratzschmar J, et al. Gene expression profiling of scrapie-infected brain tissue. Biochem Biophys Res Commun. 2004;323(2):556–64. doi:10.1016/j.bbrc.2004.08.124.View ArticlePubMedGoogle Scholar
- Xiang W, Windl O, Wunsch G, Dugas M, Kohlmann A, Dierkes N, et al. Identification of differentially expressed genes in scrapie-infected mouse brains by using global gene expression technology. J Virol. 2004;78(20):11051–60. doi:10.1128/JVI.78.20.11051-11060.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Skinner PJ, Abbassi H, Chesebro B, Race RE, Reilly C, Haase AT. Gene expression alterations in brains of mice infected with three strains of scrapie. BMC Genomics. 2006;7:114. doi:10.1186/1471-2164-7-114.PubMed CentralView ArticlePubMedGoogle Scholar
- Hwang D, Lee IY, Yoo H, Gehlenborg N, Cho JH, Petritis B, et al. A systems approach to prion disease. Mol Syst Biol. 2009;5:252. doi:10.1038/msb.2009.10.PubMed CentralView ArticlePubMedGoogle Scholar
- Moody LR, Herbst AJ, Yoo HS, Vanderloo JP, Aiken JM. Comparative prion disease gene expression profiling using the prion disease mimetic, cuprizone. Prion. 2009;3(2):99–109.PubMed CentralView ArticlePubMedGoogle Scholar
- Majer A, Medina SJ, Niu Y, Abrenica B, Manguiat KJ, Frost KL, et al. Early mechanisms of pathobiology are revealed by transcriptional temporal dynamics in hippocampal CA1 neurons of prion infected mice. PLoS Pathog. 2012;8(11):e1003002. doi:10.1371/journal.ppat.1003002.PubMed CentralView ArticlePubMedGoogle Scholar
- Carroll JA, Striebel JF, Race B, Phillips K, Chesebro B. Prion infection of mouse brain reveals multiple new upregulated genes involved in neuroinflammation or signal transduction. J Virol. 2015;89(4):2388–404. doi:10.1128/JVI.02952-14.PubMed CentralView ArticlePubMedGoogle Scholar
- Marsh RF, Bessen RA, Lehmann S, Hartsough GR. Epidemiological and experimental studies on a new incident of transmissible mink encephalopathy. J Gen Virol. 1991;72(Pt 3):589–94.View ArticlePubMedGoogle Scholar
- Bessen RA, Marsh RF. Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters. J Gen Virol. 1992;73(Pt 2):329–34.View ArticlePubMedGoogle Scholar
- Eckroade RJ, ZuRhein GM, Hanson RP. Transmissible mink encephalopathy in carnivores: clinical, light and electron microscopic studies in raccons, skunks and ferrets. J Wildl Dis. 1973;9(3):229–40.View ArticlePubMedGoogle Scholar
- Johnson CJ, Herbst A, Duque-Velasquez C, Vanderloo JP, Bochsler P, Chappell R, et al. Prion protein polymorphisms affect chronic wasting disease progression. PLoS One. 2011;6(3):e17450. doi:10.1371/journal.pone.0017450.PubMed CentralView ArticlePubMedGoogle Scholar
- Huang da W, Sherman BT, Zheng X, Yang J, Imamichi T, Stephens R et al. Extracting biological meaning from large gene lists with DAVID. Current protocols in bioinformatics / editoral board, Andreas D Baxevanis et al. 2009;Chapter 13:Unit 13 1. doi:10.1002/0471250953.bi1311s27.Google Scholar
- Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, et al. Ensembl 2014. Nucleic Acids Res. 2014;42(Database issue):D749–55. doi:10.1093/nar/gkt1196.PubMed CentralView ArticlePubMedGoogle Scholar
- Kinsella RJ, Kahari A, Haider S, Zamora J, Proctor G, Spudich G, et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxford). 2011;2011:bar030. doi:10.1093/database/bar030.View ArticleGoogle Scholar
- Dandoy-Dron F, Guillo F, Benboudjema L, Deslys JP, Lasmezas C, Dormont D, et al. Gene expression in scrapie. Cloning of a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts. J Biol Chem. 1998;273(13):7691–7.View ArticlePubMedGoogle Scholar
- Dron M, Dandoy-Dron F, Guillo F, Benboudjema L, Hauw JJ, Lebon P, et al. Characterization of the human analogue of a Scrapie-responsive gene. J Biol Chem. 1998;273(29):18015–8.View ArticlePubMedGoogle Scholar
- Baehrecke EH, Dang N, Babaria K, Shneiderman B. Visualization and analysis of microarray and gene ontology data with treemaps. BMC Bioinformatics. 2004;5:84. doi:10.1186/1471-2105-5-84.PubMed CentralView ArticlePubMedGoogle Scholar
- Kimberlin RH, Cole S, Walker CA. Temporary and permanent modifications to a single strain of mouse scrapie on transmission to rats and hamsters. J Gen Virol. 1987;68(Pt 7):1875–81.View ArticlePubMedGoogle Scholar
- Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med. 1998;4(10):1157–65. doi:10.1038/2654.View ArticlePubMedGoogle Scholar
- Huang L, Harvie G, Feitelson JS, Gramatikoff K, Herold DA, Allen DL, et al. Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics. 2005;5(13):3314–28. doi:10.1002/pmic.200401277.View ArticlePubMedGoogle Scholar
- Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 1995;57(1):289–300. doi:10.2307/2346101.Google Scholar
- Guberman JM, Ai J, Arnaiz O, Baran J, Blake A, Baldock R, et al. BioMart Central Portal: an open database network for the biological community. Database (Oxford). 2011;2011:bar041. doi:10.1093/database/bar041.View ArticleGoogle Scholar